Cortagen: Evidence, Mechanism, Dosing & Legal Status

Cortagen is a synthetic tetrapeptide developed in the Russian peptide-bioregulator program led by Vladimir Khavinson, designed as a defined-sequence stand-in for Cortexin, an older cattle-brain-cortex polypeptide extract used in Russian neurology.13 Its popularity in longevity and nerve-recovery circles outruns its proof in humans by a wide margin. This monograph separates the two.

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. Cortagen is not an FDA-approved drug; it is sold as a "research chemical not for human use." Dosing figures are reported strictly as seen in the published literature for completeness — not as recommendations. Consult a licensed clinician before any health decision.

What is Cortagen and how does it work?

Cortagen is the tetrapeptide alanyl-glutamyl-aspartyl-proline (Ala-Glu-Asp-Pro, "AEDP"), molecular formula C₁₇H₂₆N₄O₉, molecular weight about 430.4 g/mol, catalogued as PubChem CID 18439621.10 It was obtained by directed synthesis based on amino-acid analysis of Cortexin and is one member of the broader "cytogen" short-peptide family, with the cerebral cortex and nervous system as its proposed tissue target.3 Note that AEDP (Cortagen, proline) is chemically distinct from AEDG (Epitalon, glycine) and from the Cortexin/AEDG complexes — vendor pages frequently conflate these.

The proposed mechanism is unconventional and, importantly, hypothesis-grade. Unlike receptor-binding peptides, the Khavinson hypothesis holds that di-, tri-, and tetrapeptides are small enough to cross the plasma and nuclear membranes without receptor-mediated transport, then bind specific DNA sequences in gene-promoter regions through electrostatic and steric complementarity, modulating chromatin condensation and tissue-specific transcription.78 Independent biophysical support for nuclear uptake of this peptide class — not Cortagen specifically — comes from fluorescence-labeled short peptides penetrating HeLa-cell nuclei and binding deoxyoligonucleotides in vitro.9 For Cortagen itself, a cDNA-microarray study of mouse heart found 234 clones (1.53%) with altered expression matching 110 known genes, demonstrating that the peptide measurably shifts tissue gene-expression profiles.3 In aged-lymphocyte chromatin, Cortagen has been reported to decondense "old" heterochromatin and reactivate ribosomal genes.6

The critical caveat: this "peptide-into-the-nucleus-binds-DNA" model is largely advanced by one research network and remains mechanistically unconventional and not broadly independently validated. Effect sizes, dosing nonlinearity, and the in-vivo relevance of in-vitro DNA binding are unresolved. No formal pharmacokinetic dataset for Cortagen was identified; as an unprotected linear tetrapeptide it is expected to undergo rapid proteolytic degradation with a very short plasma half-life and negligible oral bioavailability — consistent with why animal studies used parenteral dosing.

What is the evidence by indication?

Every indication below is best understood as animal-model evidence. There are no human RCTs for any of them.

The anchor study is the most cited and the most extrapolated. Male Wistar rats with a transected and sutured sciatic nerve received intramuscular Cortagen 10 micrograms per kilogram for 10 days; the growth rate and conduction velocity of regenerating fibers rose 27% and 40%, respectively.1 A follow-up assessed late regeneration at five months post-injury and reported persistence of the regenerative effect into the remyelination phase rather than a transient bump.2 These are small, single-laboratory, same-group studies, and the widely repeated claim of a "pronounced therapeutic effect" on human peripheral nerve recovery is not backed by a retrievable controlled human trial.

For brain neuroprotection, rats with chronic cerebral ischemia treated with Cortexin and Cortagen showed accelerated recovery of disturbed behavior, prevention of excessive lipid peroxidation, and preserved brain antioxidant activity.4 A related paper reported neuroprotective effects during ischemic preconditioning.5 Real, measurable tissue gene-expression shifts were shown by microarray, but the leap from "alters gene expression in mouse heart" to "anti-aging in humans" remains unproven.3 Readers can confirm the absence of registered human trials directly via ClinicalTrials.gov.

What doses appear in the literature?

Reported strictly as information, not a protocol. The animal nerve-regeneration dose was Cortagen 10 micrograms per kilogram intramuscular, once daily for 10 days post-injury in rats; behavioral and locomotor work referenced an "optimal" dose around 0.03 milligrams per kilogram in mice.1 There is no validated human dose. Russian-marketed bioregulator products are sold as oral capsules and as lyophilized powder for injection, but "protocols" circulated by research-chemical vendors — for example, 2 to 10 milligrams reconstituted, subcutaneous, in cycles — are not derived from controlled human trials and are not endorsed here. Lyophilized peptide vials of this class are typically reconstituted with bacteriostatic water and refrigerated, but specifics vary by product and lie outside any validated clinical standard. Because the tetrapeptide is expected to degrade rapidly with low oral bioavailability, the controlled animal data used parenteral administration; oral systemic efficacy is unproven.

How safe is Cortagen?

The human safety dataset is essentially absent. No peer-reviewed human safety or adverse-event study was identified, so "well tolerated" claims rest on animal work and uncontrolled Russian clinical use — and absence of reported harm is not the same as demonstrated safety. Locomotor and anxiety studies of this peptide class reported enhanced motor activity without anxiety or emotional-affective disturbance at the tested dose, and no overt adverse effects on acute or sub-chronic dosing in rodents.4 The dominant theoretical risk is mechanistic: any agent proposed to modulate gene expression and stimulate tissue regeneration carries a theoretical concern in malignancy and in actively dividing tissues, which has not been formally studied for Cortagen. Injectable use of non-pharmaceutical-grade research-chemical peptides also carries contamination, endotoxin, sterility, and mislabeling risks independent of the molecule itself. No interaction studies exist. Pregnancy and lactation (no reproductive-toxicity data), children, and individuals with active or recent cancer should be treated as contraindicated by default.

What is the FDA and WADA status?

Cortagen is not approved as a drug in the United States. It is not listed on the FDA's 503A compounding bulk-substance lists and is not an FDA-recognized compounding substance; it is sold in the US only by research-chemical suppliers labeled "for research use only / not for human consumption," which confers no legal pathway to human therapeutic use.12 No EMA, MHRA, Health Canada, or TGA approval was identified. Within Russia, Cortexin is a registered drug and Cortagen-type bioregulators are marketed largely as supplements or registered preparations — but this does not equate to evidence by Western RCT standards.

For athletes, Cortagen is not specifically named on the 2026 WADA Prohibited List; however, as a substance not approved for human therapeutic use by any government regulatory authority, an injectable form is captured by the S0 "Non-Approved Substances" catch-all and should be treated as prohibited at all times.13 Any WADA-tested athlete should re-verify against the current list before competition.

Bottom line. Cortagen pairs one concrete, intriguing preclinical signal — faster rat sciatic-nerve regeneration, sustained to five months — with a near-total absence of human proof. What is proven is that it changes gene expression and accelerates nerve repair in rodents; what is hyped is every human therapeutic claim. Graded C overall, with no human RCTs, no FDA approval, and anti-doping liability, it is promising biology, not a validated human therapeutic. Regulatory and anti-doping facts here are current as of June 2026 and should be re-verified directly before relying on them.